Complex Information for Anesthesiologists Presented Quickly and Clearly

*ENIGMA II trial cardiac risk factors included history of coronary artery disease, heart failure, cerebrovascular disease, or peripheral vascular disease, or age ≥70 yr with other comorbiditiesInfographic created by Holly B. Ende, Vanderbilt University Medical Center; James P. Rathmell, Brigham and Women’s Health Care/Harvard Medical School; and Jonathan P. Wanderer, Vanderbilt University Medical Center. Illustration by Annemarie Johnson, Vivo Visuals Studio. Address correspondence to Dr. Ende: holly.ende@vumc.org.

1.
Myles
PS
,
Leslie
K
,
Chan
MTV
,
Forbes
A
,
Paech
MJ
,
Peyton
P
,
Silbert
BS
,
Pascoe
E
,
and the ENIGMA Trial Group
:
Avoidance of nitrous oxide for patients undergoing major surgery.
Anesthesiology
2007
;
107
:
221
31
2.
Myles
PS
,
Leslie
K
,
Chan
MTV
,
Forbes
A
,
Peyton
PJ
,
Paech
MJ
,
Beattie
WS
,
Sessler
DI
,
Devereaux
PJ
,
Silbert
B
,
Schricker
T
,
Wallace
S
;
ANZCA Trials Group for the ENIGMA-II investigators
:
The safety of addition of nitrous oxide to general anaesthesia in at-risk patients having major non-cardiac surgery (ENIGMA-II): A randomised, single-blind trial.
Lancet
2014
;
384
:
1446
54
3.
Peyton
PJ
,
Liskaser
G
,
Ho
A
,
Marsh
H
,
Etherington
C
,
Torlot
F
,
Desai
M
,
Perrett
G
,
Chee
B
,
Leslie
K
,
Myles
PS
:
Postoperative pulmonary complications in the ENIGMA II Trial: A post hoc analysis.
Anesthesiology
2023
;
138
:
354
63